# Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%

> **NCT01893567** · PHASE4 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 28 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Clobex Spray

## Key facts

- **NCT ID:** NCT01893567
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01893567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01893567, "Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01893567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*